INDOCYANINE GREEN- indocyanine green and water
HUB Pharmaceuticals LLC

Indocyanine Green for Injection USP
Rx only

DESCRIPTION
Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.

Indocyanine green is a water-soluble, tricarbocyanine dye with peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1H-benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indo-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-1H-benz[e]indolium hydroxide, inner salt, sodium, or 2-[7-[1,1-dimethyl-3-(4-sulfobutyl)benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-1H-benz[e]indolium hydroxide, inner salt, sodium salt. Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted. Each vial of Indocyanine Green for Injection USP contains 25 mg of indocyanine green as a sterile lyophilized powder.

CLINICAL PHARMACOLOGY
Following intravenous injection, Indocyanine Green is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). Indocyanine Green undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. Indocyanine Green is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. These characteristics make Indocyanine Green a helpful index of hepatic function.

The plasma fractional disappearance rate at the recommended 0.5 mg/kg dose has been reported to be significantly greater in women than in men, although there was no significant difference in the calculated value for clearance.

INDICATIONS AND USAGE
For determining cardiac output, hepatic function and liver blood flow, and for opthalmic angiography.

CONTRAINDICATIONS
Indocyanine Green for Injection USP contains sodium iodide and should be used with caution in patients...
who have a history of allergy to iodides.

**WARNINGS**

Anaphylactic deaths have been reported following Indocyanine Green for Injection USP administration during cardiac catheterization.

**PRECAUTIONS**

**General**

Indocyanine Green Powder and Solution: Indocyanine Green is unstable in aqueous solution and must be used within 6 hours. However, the dye is stable in plasma and whole blood so that samples obtained in discontinuous sampling techniques may be read hours later. Sterile techniques should be used in handling the dye solution as well as in the performance of the dilution curves.

Indocyanine Green powder may cling to the vial or lump together because it is freeze-dried in the vials.

**Drug Interactions**

Heparin preparations containing sodium bisulfite reduce the absorption peak of Indocyanine Green in blood and, therefore, should not be used as an anticoagulant for the collection of samples for analysis.

**Drug/Laboratory Test Interactions**

Radioactive iodine uptake studies should not be performed for at least a week following the use of Indocyanine Green.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

No studies have been performed to evaluate the carcinogenicity, mutagenicity, or impairment of fertility.

**Pregnancy: Teratogenic Effects: Pregnancy Category C**

Animal Reproduction studies have not been conducted with Indocyanine Green. It is also not known whether Indocyanine Green can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Indocyanine Green should be given to a pregnant woman only if clearly indicated.

**Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Indocyanine Green is administered to a nursing woman.

**Pediatric Use**

Safety and effectiveness in pediatric patients have been established.

**Geriatric Use**

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

**ADVERSE REACTIONS**

Anaphylactic or urticarial reactions have been reported in patients with or without history of allergy to iodides. If such reactions occur, treatment with the appropriate agents (e.g., epinephrine, antihistamines, and corticosteroids) should be administered.
OVERDOSAGE

There are no data available describing the signs, symptoms, or laboratory findings accompanying overdosage. The LD₅₀ after I.V. administration ranges between 60 and 80 mg/kg in mice, 50 and 70 mg/kg in rats and 50 and 80 mg/kg in rabbits.

DOSAGE AND ADMINISTRATION

Indicator-Dilution Studies

Indocyanine Green permits recording of the indicator-dilution curves for both diagnostic and research purposes independently of fluctuations in oxygen saturation. In the performance of dye dilution curves, a known amount of dye is usually injected as a single bolus as rapidly as possible via a cardiac catheter into selected sites in the vascular system. A recording instrument (oximeter or densitometer) is attached to a needle or catheter for sampling of the dye-blood mixture from a systematic arterial sampling site.

Under sterile conditions, the Indocyanine Green for Injection USP powder should be dissolved with Sterile Water for Injection, USP, and the solution used within 6 hours after it is prepared. If a precipitate is present, discard the solution. The amount of solvent to be used can be calculated from the dosage form which follows. It is recommended that the syringe used for injection of the dye be rinsed with this diluent. Saline is used in all other parts of the catheterization procedure.

This matter of rinsing the dye syringe with distilled water may not be critical, since it is known that an amount of sodium chloride sufficient to make an isotonic solution may be added to dye that has first been dissolved in distilled water. This procedure has been used for constant-rate injection techniques without precipitation of the dye.

The usual doses of Indocyanine Green which have been used for dilution curves are as follows:

- Adults—5 mg
- Children—2.5 mg
- Infants—1.25 mg

These doses of the dye are usually injected in a 1-mL volume. An average of five dilution curves is required in the performance of a diagnostic cardiac catheterization. The total dose of dye injected should be kept below 2 mg/kg.

Calibrating Dye Curves

To quantitate the dilution curves, standard dilutions of Indocyanine Green in whole blood are made as follows: It is strongly recommended that the same dye that was used for the injections be used in the preparation of these standard dilutions. The most concentrated dye solution is made by accurately diluting 1 mL of the 5-mg/mL dye with 7 mL of distilled water. This concentration is then successively halved by diluting 4 mL of the previous concentration with 4 mL of distilled water. (If a 2.5 mg/mL concentration was used for the dilution curves, 1 mL of the 2.5 mg/mL dye is added to 3 mL of distilled water to make the most concentrated "standard" solution. This concentration is then successively halved by diluting 2 mL of the previous concentration with 2 mL of distilled water.) Then 0.2-mL portions (accurately measured from a calibrated syringe) of these dye solutions are added to 5-mL aliquots of the subject's blood, giving final concentrations of the dye in blood beginning with 24 mg/liter, approximately (actual concentration depends on the exact volume of dye added). This concentration is, of course, successively halved in the succeeding aliquots of the subject's blood. These aliquots of blood containing known amounts of dye, as well as a blank sample to which 0.2 mL of saline containing no dye has been added, are then passed through the detecting instrument and a calibration curve is constructed from the deflections recorded.
Hepatic Function Studies

Due to its absorption spectrum, changing concentrations of Indocyanine Green in the blood can be monitored by ear densitometry or by obtaining blood specimens at timed intervals. The technique for both methods is as follows.

The patient should be studied in a fasting, basal state. The patient should be weighed and the dosage calculated on the basis of 0.5 mg/kg of body weight.

Under sterile conditions, the Indocyanine Green for Injection USP powder should be dissolved with Sterile Water for Injection, USP. Exactly 5 mL of Sterile Water for Injection, USP, should be added to the 25-mg vial, giving 5 mg of dye per mL of solution.

Inject the correct amount of dye into the lumen of an arm vein as rapidly as possible, without allowing the dye to escape outside the vein. (If the photometric method is used, prior to injecting Indocyanine Green, withdraw 6 mL of venous blood from the patient's arm for serum blank and standard curve construction, and through the same needle, inject the correct amount of dye.)

Ear Densitometry

Ear oximetry has also been used and makes it possible to monitor the appearance and disappearance of Indocyanine Green without the necessity of withdrawal and spectrophotometric analysis of blood samples for calibration. An ear densitometer which has a compensatory photo-electric cell to correct for changes in blood volume and hematocrit, and a detection photocell which registers levels has been described. This device permits simultaneous measurement of cardiac output, blood volume and hepatic clearance of Indocyanine Green* and was found to provide a reliable index of plasma removal kinetics after single injections or continuous infusions of Indocyanine Green. This technique was employed in newborn infants, healthy adults and in children and adults with liver disease. The normal subject has a removal rate of 18-24% per minute. Due to the absence of extra-hepatic removal, Indocyanine Green was found to be ideally suited for serial study of severe chronic liver disease and to provide a stable measurement of hepatic blood flow. In larger doses, Indocyanine Green has proven to be particularly valuable in detecting drug-induced alterations of hepatic function and in the detection of mild liver injury.

Using the ear densitometer, a dosage of 0.5 mg/kg in normal subjects gives the following clearance pattern.
Photometric Method

Determination Using Percentage Retention of Dye

A typical curve obtained by plotting dye concentration versus optical density is shown opposite. Percent retention can be read from this plot.

If more accurate results are desired, a curve using the patient's blood and the vial of Indocyanine Green being used in the determination can be constructed as follows:

1. Take 6 mL of non-dye-containing venous blood from the patient's arm. Place in a test tube and allow the blood to clot. The serum is separated by centrifugation.
2. Pipette 1 mL of the serum into a microcuvette.
3. Add 1 lambda (\(\lambda\)) of the 5-mg/mL aqueous Indocyanine Green solution to the serum, giving a dilution of 5 mg/liter, the standard for 50% retention. (The addition of 2 lambda (\(\lambda\)) of the 5-mg/mL Indocyanine
Green solution would give 100% retention; however, this concentration cannot be read on the spectrophotometer.

4. The optical density of this solution is read at 805 nm, using normal serum as the blank.

5. Plot the 50% figure obtained in Step 4, and draw a line connecting this point with the zero coordinates.

**Percentage Retention**

A single 20-minute sample (withdrawn from a vein in the opposite arm to that injected) is allowed to clot, centrifuged, and its optical density is determined at 805 nm using the patient's normal serum as the blank. Dye concentration is read from the curve above. A single 20-minute sample of serum in healthy subjects should contain no more than 4% of the initial concentration of the dye. The use of percentage retention is less accurate than percentage disappearance rate but provides reproducible results. Hemolysis does not interfere with a reading.

**Determination Using Disappearance Rate of Dye**

To calculate the percentage disappearance rate, obtain samples at 5, 10, 15 and 20 minutes after injecting the dye. Prepare the sample as in the previous section and measure the optical densities at 805 nm, using the patient's normal serum as the blank. The Indocyanine Green concentration in each timed specimen can be determined by using the concentration curve illustrated. Plot values on semilogarithmic paper.

Specimens containing Indocyanine Green should be read at the same temperature since its optical density is influenced by temperature variations.

**Normal Values:** Percentage disappearance rate in healthy subjects is 18-24% per minute. Normal biological half-time is 2.5-3.0 minutes.

**Ophthalmic Angiography Studies**

The excitation and emission spectra (Figure 1) and the absorption spectra (Figure 2) of Indocyanine Green make it useful in ophthalmic angiography. The peak absorption and emission of Indocyanine Green lie in a region (800-850 nm) where transmission of energy by the pigment epithelium is more efficient than in the region of visible light energy. Indocyanine Green also has the property of being nearly 98% bound to blood protein, and therefore, excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature. It is, therefore, useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.
Dosages up to 40 mg Indocyanine Green dye in 2 mL of Sterile Water for Injection, USP, have been found to give optimal angiograms, depending on the imaging equipment and technique used. The antecubital vein injected Indocyanine Green dye bolus should immediately be followed by a 5-mL bolus of normal saline.

Clinically, angiograms of uniformly good quality can be assured only after taking care to optimize the contributions of all possible factors, such as patient cooperation and dye injection. The foregoing injection regimen is designed to provide delivery of a spatially limited dye bolus of optimal concentration to the choroidal vasculature following intravenous injection.

HOW SUPPLIED
Indocyanine Green for Injection USP, is supplied in a kit, (NDC 17238-424-02) containing six 25-mg Indocyanine Green for Injection USP vials and six 10-mL Sterile Water for Injection vials:

NDC 17238-424-01 Indocyanine Green for Injection 25-mg fill in 30-mL vial.
NDC 63323-185-10 (or NDC 0409-4887-17) Sterile Water for Injection 10-mL fill in 10-mL vial.

**STORAGE**

Store at 20° to 25° C (68 to 77 °F). [See USP Controlled Room Temperature.]

**Manufactured by:**
Patheon Italia S.p.A.
20900 Monza (MB), ITALY

**Distributed by:**
HUB Pharmaceuticals LLC
Rancho Cucamonga, CA 91730

**Sterile Water for Injection, USP is Manufactured by:**
Fresenius Kabi USA, LLC
Grand Island, NY 14072 USA
or
Hospira, Inc.
Rocky Mount, NC 27804 USA

50429 Rev. 2/16

Principal Display Panel - Carton

NDC 17238-424-06

**Indocyanine Green for Injection, USP**

For Intravenous Administration
25 mg/Vial Kit
Rx Only - Sterile

**Indocyanine Green**
for Injection USP

DIRECTIONS FOR USE ENCLOSED

CAUTION: To ensure accurate readings, Indocyanine Green, USP dissolved in Sterile Water for Injection, USP must be used within 6 hours.

STORAGE: Store at 20° to 25°C (68° to 77°F)
[See USP Controlled Room Temperature].

USAGE: See package insert for dosage information.

25 mg/Vial Kit

Indocyanine Green
for Injection USP

Distributed by

HUB Pharmaceuticals LLC

9339 Charles Smith Ave., Bldg. 150
Rancho Cucamonga, CA 91730
1-800-EYE-DROP (393-3767)

Manufactured by:

Patheon Italia S.p.A.
Viale G.B. Stucchi 110
20900 Monza (MB) ITALY

Sterile Water Manufactured by:

Hospira, Inc.
Rocky Mount, NC 27804

Fresenius Kabi USA, LLC
Grand Island, NY 14072

Rx only

25 mg/Vial Kit

NDC 17238-424-06

Indocyanine Green
for Injection, USP

Contents:
Six Indocyanine Green for injection, USP vials (25 mg each)
Six Sterile Water for Injection, USP Vials (10 mL each)

For Intravenous Administration

25 mg/Vial Kit

Rx Only - Sterile

07/2017

Principal Display Panel - Sterile Water Vial
100mL
Single-dose

WARNINGS: NOT ISOTONIC. HEMOLYTIC.
NDC 0409-4887-25
Rx only
Sterile Water
for Inj., USP
FOR DRUG DILUTENT USE ONLY
Hospira, Inc., Lake Forest, IL 60045 USA

Contains no antimicrobial or other added substance.
Single dose container. DO NOT GIVE INTRAVENOUSLY UNLESS RENDERED NEARLY ISOTONIC. Sterile, nonpyrogenic.

Usual dosage: See insert.
Store at 20 to 25 °C (68 to 77 °F). [See USP Controlled Room Temperature.] Protect from freezing.

RL-4469
Hospira
Rx only

10 mL Single Dose Vial
Sterile, Nonpyrogenic

Preservative Free

Discard unused portion.

Do not administer intravenously unless rendered nearly isotonic.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

APP

APP Pharmaceuticals, LLC
Schaumburg, IL 60173
401753E
LOT/EXP 63323-185-10

Principal Display Panel - Vial

Indocyanine Green for Injection, USP
25 mg/Vial

For Intravenous Administration
After reconstitution, use within 6 hours

Rx only Sterile

Manufactured by: Patheon Italia S.p.A.
Distributed by: HUB Pharmaceuticals LLC

NDC17238-424-25
Indocyanine Green for Injection USP
25 mg/Vial
For Intravenous Administration

After reconstitution use within 6 hours.

Rx only Sterile
Manufactured by: Patheon Italia S.p.A.
Distributed by: HUB Pharmaceuticals LLC
Lot. No.

Exp.
Barcode Number: 317238424257
50431

<table>
<thead>
<tr>
<th>INDOCYANINE GREEN</th>
<th>indocyanine green and water kit</th>
</tr>
</thead>
</table>

**Product Information**

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:17238-424</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Packaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>#</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quantity of Parts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part #</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>Part 1</td>
</tr>
<tr>
<td>Part 2</td>
</tr>
</tbody>
</table>

**Part 1 of 2**

INDOCYANINE GREEN
indocyanine green injection, powder, lyophilized, for solution

**Product Information**

| Route of Administration | INTRAVENOUS |

**Active Ingredient/Active Moiety**
<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDOCYANINE GREEN (UNII: IX6J1063HV)</td>
<td>INDOCYANINE GREEN</td>
<td>25 mg</td>
</tr>
<tr>
<td>(INDOCYANINE GREEN ACID FORM - UNII:C4V974V932)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM IODIDE (UNII: F5WR8N145C)</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA040811</td>
<td>01/01/2008</td>
<td></td>
</tr>
</tbody>
</table>

**Part 2 of 2**

**STERILE WATER**

*water injection, solution*

**Product Information**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>INTRAVENOUS</th>
</tr>
</thead>
</table>

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td>WATER</td>
<td>10 mL</td>
</tr>
<tr>
<td>(WATER - UNII:059QF0KO0R)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA088400</td>
<td>01/16/1984</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA040811</td>
<td>01/01/2008</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - HUB Pharmaceuticals LLC (611747945)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospira, Inc.</td>
<td>093132819</td>
<td>manufacture(17238-424)</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Address</td>
<td>ID/FEI</td>
<td>Business Operations</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------</td>
<td>------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Fresenius Kabi USA, LLC</td>
<td></td>
<td>840771732</td>
<td>manufacture(17238-424)</td>
</tr>
</tbody>
</table>

Revised: 11/2019

HUB Pharmaceuticals LLC